Akorn price target raised to $60 from $50 at Guggenheim Guggenheim raised Buy rated Akron's price target to $60 from $50 following the Q4 report. The analyst believes Akorn is well positioned for upward earnings revisions that will drive shares higher in 2015.
Akorn sees Q1 revenue down sequentially from Q4 Q1 revenue consensus $217.62M. The company said: "Based on several previously disclosed factors contributing to Q4 performance including higher-than-normal in-transit revenue at the end of the Q3, seasonality in the Hi-Tech Pharmacal cough and cold business and the successful resolution of backorders from the third quarter encountered due to clobetasol market dynamics, the company believes 1Q15 revenue will be below 4Q14 revenue. Akorn projects that consolidated net revenue will increase sequentially throughout 2015 due to a combination of seasonality in the business and the cumulative impact of new launches on quarterly revenue throughout the year."